Advertisement


Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide

2020 Genitourinary Cancers Symposium

Advertisement

Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses results from the CARD study, which showed that cabazitaxel improved pain, time to pain progression, and symptomatic skeletal events, as well as quality of life in patients with metastatic castration-resistant prostate cancer. The findings support the use of this agent as a standard of care (Abstract 16).



Related Videos

Immunotherapy
Bladder Cancer

Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses study results which showed that, in first-line cisplatin-ineligible patients with metastatic u...

Prostate Cancer

Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness

Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in ...

Bladder Cancer

Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy

Syed A. Hussain, MD, of the University of Sheffield, discusses phase II findings comparing nintedanib or placebo in combination with gemcitabine and cisplatin in locally adva...

Kidney Cancer

Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses findings from a phase I/II trial that found MK-6482 was well tolerated and demonstrated activity in heavily p...

Kidney Cancer
Immunotherapy

Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Potential Determinants of Poor Prognosis and Treatment Response

Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses two types of renal cell cancer that are associated with poor prognosis. Because recent early data suggest these t...

Advertisement

Advertisement



Advertisement